A Study of WF 10 IV Solution in Patients With Advanced HIV Disease

Inclusion Criteria Concurrent Medication: Allowed: Approved drugs at a stabilized dose except those specifically excluded. Aerosolized pentamidine (300 mg) once a month for PCP prophylaxis. Patients must have: HIV positivity. Absolute CD4 count < 200 cells/mm3. Intolerance to or refusal to take AZT, ddI, ddC, or d4T. No active opportunistic infection requiring ongoing therapy. Life expectancy at least 3 months. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Neoplasm other than basal cell carcinoma of the skin. Clinically significant cardiac disease. Anemia. Concurrent Medication: Excluded: Cytotoxic chemotherapy. Corticosteroids. Patients with the following prior conditions are excluded: History of myocardial infarction or arrhythmias. Prior Medication: Excluded within 2 weeks prior to study entry: Any antiretroviral agent. Interferon. Systemic therapy with biologic response modifiers, corticosteroids, cytotoxic chemotherapy, or neutropenic or nephrotoxic drugs. Excluded within 30 days prior to study entry: Investigational drugs. Prior Treatment: Excluded within 2 weeks prior to study entry: Radiation therapy. Active drug or alcohol abuse.